Haemonetics Corporation (HAE) Shares Bought by Principal Financial Group Inc.

Principal Financial Group Inc. boosted its stake in Haemonetics Corporation (NYSE:HAE) by 7.1% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 434,390 shares of the medical instruments supplier’s stock after purchasing an additional 28,812 shares during the quarter. Principal Financial Group Inc. owned about 0.83% of Haemonetics Corporation worth $17,154,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the business. Airain ltd purchased a new stake in Haemonetics Corporation in the 2nd quarter worth $321,000. Bridge City Capital LLC purchased a new stake in Haemonetics Corporation in the 2nd quarter worth $1,050,000. American Century Companies Inc. lifted its stake in Haemonetics Corporation by 0.9% in the 2nd quarter. American Century Companies Inc. now owns 46,271 shares of the medical instruments supplier’s stock worth $1,827,000 after purchasing an additional 425 shares in the last quarter. BNP Paribas Arbitrage SA lifted its stake in Haemonetics Corporation by 63.8% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 17,996 shares of the medical instruments supplier’s stock worth $711,000 after purchasing an additional 7,009 shares in the last quarter. Finally, Legal & General Group Plc lifted its stake in Haemonetics Corporation by 9.4% in the 2nd quarter. Legal & General Group Plc now owns 99,893 shares of the medical instruments supplier’s stock worth $3,943,000 after purchasing an additional 8,543 shares in the last quarter.

COPYRIGHT VIOLATION WARNING: “Haemonetics Corporation (HAE) Shares Bought by Principal Financial Group Inc.” was first reported by Transcript Daily and is the property of of Transcript Daily. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The original version of this news story can be accessed at https://transcriptdaily.com/2017/09/17/haemonetics-corporation-hae-shares-bought-by-principal-financial-group-inc.html.

Several analysts have commented on HAE shares. Jefferies Group LLC reiterated a “buy” rating and issued a $48.00 price target on shares of Haemonetics Corporation in a research note on Thursday, July 27th. Zacks Investment Research cut shares of Haemonetics Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday, August 16th. TheStreet upgraded shares of Haemonetics Corporation from a “c” rating to a “b-” rating in a research note on Monday, August 7th. BidaskClub cut shares of Haemonetics Corporation from a “hold” rating to a “sell” rating in a research note on Friday, June 23rd. Finally, Barrington Research upgraded shares of Haemonetics Corporation from a “market perform” rating to an “outperform” rating and set a $48.00 price target on the stock in a research note on Tuesday, August 8th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and three have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $40.71.

Shares of Haemonetics Corporation (NYSE:HAE) opened at 42.29 on Friday. Haemonetics Corporation has a 12 month low of $32.76 and a 12 month high of $43.77. The stock has a market capitalization of $2.22 billion, a PE ratio of 549.22 and a beta of 0.89. The stock’s 50 day moving average is $42.14 and its 200 day moving average is $40.82.

Haemonetics Corporation (NYSE:HAE) last posted its quarterly earnings results on Monday, August 7th. The medical instruments supplier reported $0.33 earnings per share for the quarter, topping analysts’ consensus estimates of $0.31 by $0.02. The firm had revenue of $211.00 million for the quarter, compared to analyst estimates of $211.29 million. Haemonetics Corporation had a net margin of 0.48% and a return on equity of 11.07%. Haemonetics Corporation’s quarterly revenue was up .5% on a year-over-year basis. During the same period in the previous year, the business posted $0.25 earnings per share. Analysts anticipate that Haemonetics Corporation will post $1.60 earnings per share for the current fiscal year.

About Haemonetics Corporation

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corporation (NYSE:HAE).

Institutional Ownership by Quarter for Haemonetics Corporation (NYSE:HAE)

Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply